Bacterial expression and characterization of human recombinant apolipoprotein(a) kringle IV type 9

被引:2
|
作者
Chung, FZ
Wu, LH
Lee, HT
Mueller, WT
Spahr, MA
Eaton, SR
Tian, Y
Settimi, PD
Oxender, DL
Ramharack, R
机构
[1] Warner Lambert Parke Davis, Parke Davis Pharmaceut Res, Dept Vasc & Cardiac Dis, Ann Arbor, MI 48105 USA
[2] Warner Lambert Parke Davis, Parke Davis Pharmaceut Res, Dept Biol Mol, Ann Arbor, MI 48105 USA
[3] Warner Lambert Parke Davis, Parke Davis Pharmaceut Res, Dept Med Chem, Ann Arbor, MI 48105 USA
关键词
D O I
10.1006/prep.1998.0898
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Elevated plasma lipoprotein(a) [Lp(a)] is an independent risk factor for several vascular diseases. Lp(a) particles are generated through the formation of a disulfide bond between Cys(4057) of kringle TV type 9, (KIVt9), of the multikringle apolipoprotein(a) [apo(a)] and a cysteine in apoB-100 low-density Lipoprotein (LDL). To better understand this interaction, we have expressed and purified KIVt9 from Escherichia coli as a His-Tag fusion protein. Dithiothreitol (DTT)-treated purified KIVt9 migrated as a single similar to 17.3-kDa band on SDS-PAGE gels. Without DTT, an additional band twice the molecular weight of KIVt9 was observed. The double-size band presumably resulted hom dimerization of individual kringles, through their unpaired cysteine residues, since a mutation Cys(4057) -->Ser ([Ser(4057)]KIVt9) abolished dimer formation. Using a gel-shift assay, we showed that KIVt9 could couple to 14-amino-acid apoB-100 synthetic peptides (apoB(3732-3745) and apoB(4319-4332)) containing Cys(3734) or cys(4326). Both Of these apoB-100 cysteines have been reported to associate with apo(a) to generate Lp(a). In the presence of either apoB-100 peptide, KIVt9 was shifted to a higher molecular weight that was consistent with the covalent addition of a 1.2-kDa apoE-100 peptide. Identical apoB-100 peptides in which the cysteine residues were replaced by alanine ([Ala(3734)]apoB(3732)-(3745) and [Ala(4326)]apo(B4319-4332)) had no effect in the gel-shift assay. Furthermore, [Ser(4057)]KIVt9 did not covalently interact with apoB(3732-3745) or apoB(4319-4332) These results indicated that KIVt9 couples to the Cys-apoB-100 peptides through a disulfide linkage. This system may be suitable for further investigating the apo(a)/apoB-100 coupling reaction and the structure of KIVt9 through X-ray crystallographic studies. (C) 1998 Academic Press.
引用
收藏
页码:222 / 228
页数:7
相关论文
共 50 条
  • [1] Bacterial expression and characterization of human recombinant apolipoprotein(a) kringle IV type 9 (vol 13, pg 222, 1998)
    Chung, FZ
    Wu, LH
    Lee, HT
    Mueller, WT
    Spahr, MA
    Eaton, SR
    Tian, Y
    Settimi, PD
    Oxender, DL
    Ramharack, R
    PROTEIN EXPRESSION AND PURIFICATION, 1998, 14 (01) : 153 - 153
  • [2] CLONING, EXPRESSION, AND CHARACTERIZATION OF HUMAN APOLIPOPROTEIN(A) KRINGLE IV37
    LOGRASSO, PV
    CORNELLHENNON, S
    BOETTCHER, BR
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1994, 269 (34) : 21820 - 21827
  • [3] Purification and characterization of a recombinant anti-angiogenic kringle fragment expressed in Escherichia coli:: Purification and characterization of a tri-kringle fragment from human apolipoprotein (a) (kringle IV (9)-kringle IV (10)-kringle V)
    Kang, KY
    Kim, SG
    Kim, WK
    You, HK
    Kim, YJ
    Lee, JH
    Jung, KH
    Kim, CW
    PROTEIN EXPRESSION AND PURIFICATION, 2006, 45 (01) : 216 - 225
  • [4] Expression of apolipoprotein(a) kringle IV type 9 in Escherichia coli:: demonstration of a specific interaction between kringle IV type 9 and apolipoproteinB-100
    Rahman, M
    Jia, ZC
    Gabel, BR
    Marcovina, SM
    Koschinsky, ML
    PROTEIN ENGINEERING, 1998, 11 (12): : 1249 - 1256
  • [5] Expression of a recombinant Kringle V of human apolipoprotein(a): Antibody characterization and species specificity
    Chenivesse, X
    Huby, T
    Chapman, J
    Franco, D
    Thillet, J
    PROTEIN EXPRESSION AND PURIFICATION, 1996, 8 (02) : 145 - 150
  • [6] Expression, purification and in vitro refolding of kringle IV-type 6 and kringle V of human apolipoprotein-(a)
    Hrzenjak, A
    Frank, S
    Kostner, GM
    ATHEROSCLEROSIS, 1999, 144 : 105 - 105
  • [7] Solution structure of human apolipoprotein(a) kringle IV type 6
    Maderegger, B
    Bermel, W
    Hrzenjak, A
    Kostner, GM
    Sterk, H
    BIOCHEMISTRY, 2002, 41 (02) : 660 - 668
  • [8] Pharmacokinetics of recombinant human apolipoprotein(a) kringle V in rats
    Kim, Byoung Soo
    Kim, Eun Jung
    Kim, Jang Seong
    Cheon, Gi Jeong
    Lee, Ho Jeong
    Choi, Tae Hyun
    DRUG METABOLISM REVIEWS, 2010, 42 : 273 - 274
  • [9] EXPRESSION AND CHARACTERIZATION OF APOLIPOPROTEIN(A) KRINGLE-IV TYPE-1, TYPE-2 AND TYPE-10 IN MAMMALIAN-CELLS
    SANGRAR, W
    MARCOVINA, SM
    KOSCHINSKY, ML
    PROTEIN ENGINEERING, 1994, 7 (05): : 723 - 731
  • [10] Recombinant kringle IV-10 modules of human apolipoprotein(a): Structure, ligand binding modes, and biological relevance
    Mochalkin, I
    Cheng, BS
    Klezovitch, O
    Scanu, AM
    Tulinsky, A
    BIOCHEMISTRY, 1999, 38 (07) : 1990 - 1998